01 Sep 2020 Oxurion NV reports first patient dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME) Member news
11 Aug 2020 Precigen ActoBio announces positive topline results from Phase 1b study of AG019 ActoBiotics Member news
24 Jul 2020 Gilead en Galapagos kondigen positieve Europese CHMP opinie aan voor Jyseleca® (Filgotinib) voor de behandeling van volwassenen met matige tot ernstige reumatoïde artritis Member news
02 Jul 2020 Aligos Therapeutics and KU Leuven announce collaboration for the development of a therapeutic candidate targeting Coronavirus Member news
26 Jun 2020 US multicenter study shows Idylla™ allows rapid and accurate mutation testing results across different laboratory settings Member news
17 Jun 2020 eTheRNA raises EUR 34 million in Series B financing to accelerate multiple mRNA therapeutic development programs through to clinical proof of concept Member news
08 Jun 2020 New analyses of Phase 2 Equator Clinical Program support durable efficacy of Filgotinib in Psoriatic Arthritis Member news
04 Jun 2020 Filgotinib demonstrates durable efficacy and consistent safety profile at 52 weeks in Finch 1 and 3 studies in rheumatoid arthritis Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
